Skip to search formSkip to main contentSkip to account menu

alisertib

Known as: Benzoic Acid, 4-((9-Chloro-7-(2-Fluoro-6-Methoxyphenyl)-5H-Pyrimido(5,4-d)(2)Benzazepin-2-yl)Amino)-2-Methoxy- 
A second-generation, orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with… 
National Institutes of Health

Related topics

Related topics

3 relations
Aurora Kinase ANCIt Antineoplastic Agent Terminology

Broader (1)

MLN 8237

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor
Human Aurora kinases, including Aurora kinase A (AURKA), B (AURKB), and C (AURKC), play an essential role in mitotic events such… 
2016
2016
Alisertib induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells.
Alisertib, a potent and selective Aurora kinase A inhibitor, has been demonstrated to exert potent anti-cancer effects in pre… 
2016
2016
H3S10 phosphorylation-mediated transcriptional regulation by Aurora kinase A.
2015
2015
Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma
Purpose: Aurora A kinase (AAK) is expressed exclusively during mitosis, and plays a critical role in centrosome duplication and… 
Review
2015
Review
2015
First Multicenter, Randomized Phase 3 Study in Patients (Pts) With Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (LUMIERE trial…
Background PTCL is an aggressive subgroup of NHL. Outcomes in R/R PTCL remain poor and alternative therapies are needed… 
2015
2015
Alisertib (MLN8237), a selective Aurora-A kinase inhibitor, induces apoptosis in human tongue squamous cell carcinoma cell both in vitro and in vivo
Aurora-A kinases are overexpressed in many cancer tissues and cells. Alisertib is an investigational, orally administered… 
Review
2014
Review
2014
Management of relapses after hematopoietic cell transplantation in T-cell non-Hodgkin lymphomas.
T-cell non-Hodgkin lymphomas (NHLs) are a heterogeneous group of malignancies that represent 10%-15% of all NHLs. The prognosis… 
2014
2014
U.S. Intergroup phase II trial (SWOG 1108) of alisertib, an investigational aurora A kinase (AAK) inhibitor, in patients with peripheral T-cell lymphoma (PTCL; NCT01466881).
8523 Background: AAK is a serine/threonine kinase that regulates the G2-M transition and centrosome separation during mitosis… 
2013
2013
Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237).
Alisertib (MLN8237) is an investigational potent Aurora A kinase inhibitor currently under clinical trials for hematological and… 
2012
2012
Phase I/II study of weekly paclitaxel with or without MLN8237 (alisertib), an investigational aurora A kinase inhibitor, in patients with recurrent epithelial ovarian, fallopian tube, or primary…
5021 Background: Preclinical data indicate that inhibiting aurora A kinase (AAK), a key mitotic regulator, in OC can enhance the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)